Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. In addition, the company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc.is headquartered in Golden, Colorado. Theralink Technologies, Inc. is a subsidiary of Theralink Technologies, Inc.
Frequently asked questions
What sector does Therasense Inc (THER) operate in?
Therasense Inc belongs to the Other sector and operates in the Biotechnology industry.
What is Therasense Inc (THER) current stock price?
As of the latest data, Therasense Inc stock price is $0.00, with a previous close of $0.00.
What is Therasense Inc (THER) current market capitalization?
Therasense Inc market cap is approximately 615.15 thousand.
Does Therasense Inc (THER) pay dividends?
No. Therasense Inc does not pay a dividend.
What is Therasense Inc (THER) beta (volatility) score?
Therasense Inc has a beta of 59.070, indicating very high volatility compared to the market.
